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D. Heulyn Jones,a Stefano Bresciani,a James P. Tellam,a Justyna Wojno,a
Anthony W. J. Cooper,b Alan R. Kennedya and Nicholas C. O. Tomkinson*a
The isomers of dibenzylamino-1-methylcyclohexan-1-ol and dibenzylamino-1-triﬂuoromethyl-
cyclohexan-1-ol have been prepared. The stereochemistry of these compounds was unequivocally
assigned through a combination of NMR spectroscopy and single crystal X-ray analysis. The cis-isomer of
3-N,N-dibenzylamino-1-triﬂuoromethylcyclohexanol and its derivatives display an unusual conformation-
al behaviour in both solution-phase and the solid-state, where the amino group usually adopts an axial
conformation.
Introduction
The introduction of three-dimensional shape through an
increase in the proportion of sp3 hybridised centres (Fsp3) has
been correlated to compound progress in a drug-discovery
setting.1–5 The reduction of aromatic ring count has also been
shown to have beneficial eﬀects on the development properties
of oral drug candidates, including aqueous solubility, lipo-
philicity, serum albumin binding, CyP450 inhibition and
hERG inhibition.6 Based upon these important factors there
has been significant interest in robust synthetic routes to
building blocks and fragments which confer both shape and
fixed conformation on a molecule through the introduction of
saturation.7–9
Whilst there are advantages to the reduction in the number
of aromatic rings within a compound,6 the conformational
constraints of a ring provide clear benefits in a medicinal
chemistry setting, where functional groups can be held in posi-
tions to maximise ligand–receptor interaction.10 For this
reason the introduction of functional groups on an aromatic
scaﬀold has provided significant benefits within drug-discov-
ery. In addition, there are many simple and eﬀective pro-
cedures for the formation of carbon–carbon and carbon–
heteroatom bonds on aromatic and heteroaromatic rings
allowing for the rapid introduction of diversity and complexity
on these frameworks to establish and probe structure activity
knowledge.11
A common motif found in many drug molecules is the
aminophenol functionality. This can easily be introduced
through a variety of bond construction procedures and both
the amine and hydroxyl groups provide excellent synthetic
handles through which to selectively introduce a variety of
additional groups. Introduction of this functionality on a rigid
aromatic scaﬀold can provide both hydrogen bond donor and
hydrogen bond acceptor properties along with the provision of
mildly basic and acidic functional groups. Therefore, this
pharmacophore is prevalent in many bioactive molecules.
A selection of marketed drugs which contain a 1,4-, 1,3- or 1,2-
aminophenol functionality are collected in Fig. 1. Dofetilide 1
is a class III antiarrhythmic used for the maintenance of
sinus rhythm.12 Terconazole 2 is a broad spectrum antifungal
agent which ultimately inhibits the ergosterol biosynthesis
pathway.13 Neostigmine 3 is a reversible acetylcholinesterase
inhibitor which stimulates both nicotinic and muscarinic recep-
tors.14 Ivacaftor 4 is eﬀective in the treatment of cystic fibrosis.15
Suvorexant 5 is a orexin receptor antagonist,16 approved for the
treatment of insomnia and Eltombopag 6, interacts with the
thrombopoietin receptor and leads to an increased platelet
count in patients.17 These selected examples show the diversity
in protein targets for this class of compound and highlight the
importance and prevalence of the aminophenol functionality in
compounds with profound biological activities.
From the examples outlined in Fig. 1 there are clear
benefits to the use of aromatic rings to fix the aminophenol
functionality in space. However, the correlation between
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developing an oral drug candidate and the number of aromatic
rings in a compound provides a strong impetus to develop
saturated analogues of common aromatic motifs found in
drug molecules.6 As part of an ongoing investigation we
hypothesised that saturation of the aminophenol framework
would provide a particularly useful series of aminocyclo-
hexanol fragments for discovery research. Examination of the
patent literature reveals a number of compounds which
contain the aminocyclohexanol functionality suggesting that
this grouping also has potential in the drug-discovery setting.
Recent examples include the benzoxazole 7 which has been
shown to be an mPGES-1 inhibitor and the 2-amidopyridine
derivative 8, synthesised as a potential 11β-HSD1 inhibitor
(Fig. 2).18,19
A convenient synthetic precursor to the amino cyclohexanol
framework would be a suitably N-protected derivative. A typical
example that can readily be unmasked to reveal the desired
functionality is dibenzylamino-1-methylcyclohexan-1-ol and
dibenzylamino-1-trifluoromethylcyclohexan-1-ol, which each
have six structural isomers 9–20 (Fig. 3).
Despite the prevalence of this framework in the patent lit-
erature relatively few syntheses of this scaﬀold have been
reported in the primary literature. In an isolated report, Yama-
moto described the ytterbium triflate-mediated ring opening
of epoxide 21 with dibenzylamine to give the amino alcohol 22
together with 23 as a 9 : 1 mixture of regioisomers
(Scheme 1).20 Although the stereochemistry of this product
was not unequivocally assigned it is expected that this would
be the trans-isomer 13.
In the trifluoromethyl series (15–20) only the 4-amino-1-
trifluoromethylcyclohexanol 15 has been reported, as a
mixture along with minor isomer 16.19 This mixture was pre-
pared through reaction of the dibenzylamino ketone 24 with
Ruppert’s reagent (CF3SiMe3) in the presence of tetra-n-butyl-
ammonium fluoride (TBAF) followed by acidic cleavage of the
siloxy intermediate to give the products 15 and 16 as a
Fig. 1 Drug molecules containing the 1,4-, 1,3- and 1,2-aminophenol functionalitY.
Fig. 2 Examples from recent patent literature containing the 4-amino-
cyclohexanol functionality.
Fig. 3 Possible 1-methyl- and 1-triﬂuoromethyl dibenzylaminocyclo-
hexanol isomers.
Scheme 1 Epoxide ring opening route to the 1,2-isomer.
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6 : 1 mixture of diastereoisomers (Scheme 2), the trans-isomer
15 predominating.
Whilst these isolated reports are of use to those wishing to
exploit this functionality in their eﬀorts, the synthesis and
stereochemical assignment of all twelve isomers of this cyclo-
hexyl motif would be of direct use in adding stereochemical
complexity and 3-dimensional shape to discovery projects.
Within this paper we describe the synthesis, isolation and
purification of all 1-methyl- and 1-trifluoromethyl dibenzyl-
aminocyclohexan-1-ol isomers 9–20 in three steps or fewer
from readily available precursors, and unequivocally assign
their stereochemistry based upon NMR spectroscopy and X-ray
crystallographic experiments.
Results and discussion
Our investigations began with the preparation of the 4-dibenz-
ylamino derivatives 9, 10, 15 and 16 which were accessed from
the common intermediate 24. Dibenzylation of 4-aminocyclo-
hexanol hydrochloride 25 followed by Swern oxidation pro-
vided the known ketone 24 in 84% yield (Scheme 3).21
Treatment of a THF solution of 24 with methylmagnesium
chloride at −78 °C and allowing the reaction mixture to warm
slowly to room temperature followed by an acidic workup pro-
vided access to the two diastereoisomers 10 and 9 in a 70 : 30
ratio, which were separated by column chromatography provid-
ing the products in 56% (10) and 18% (9) isolated yields
(Scheme 4).
The stereochemistry of each isomer was confirmed by X-ray
crystallographic analysis (Fig. 4). The cis-isomer 10 showed two
crystallographically independent molecules within the unit
cell characterised by slightly diﬀerent conformations of the
cyclohexane ring which formed a hydrogen-bonded closed
tetramer of molecules.
Introduction of the trifluoromethyl group was achieved
under standard conditions using Ruppert’s reagent in the
presence of TBAF, delivering the two diastereomeric products
15 and 16 in a 9 : 1 ratio as determined by 1H NMR and 19F
NMR spectroscopy (Scheme 5). Although a small amount of
the major diastereomer was purified by column chromato-
graphy, eﬃcient separation of 15 and 16 could not be achieved
due to their similar aﬃnities to silica, and the mixture of dia-
stereomers was isolated in 81% yield. X-Ray crystallography
showed the major diastereoisomer from this transformation to
be the trans-isomer 15 where the trifluoromethyl group had
been introduced in an axial position.
The complete reversal of cis/trans selectivity when compared
to methyl analogues 9 and 10 is likely due to pre-complexation
of the approaching nucleophile in the addition of the Grignard
reagent, whereas the axial addition of the trifluoromethyl
group relieves gauche interactions within the transition state.22–24
Although the cis-diastereoisomer 16 was present within the
crude reaction mixture, its isolation proved challenging. We
therefore examined alternative synthetic strategies to access
this isomer. Initial attempts at using stoichiometric amounts
Scheme 2 Preparation of the triﬂuoromethyl substituted 1,4-isomer 15.
Scheme 3 Preparation of 4-dibenzylaminocyclohexanone 24.
Scheme 4 Synthesis of cis- and trans-4-dibenzylamino-1-methyl-
cyclohexanol 10 and 9.
Fig. 4 X-Ray crystal structures of 10 and 9.
Scheme 5 Synthesis of 4-dibenzylamino-1-triﬂuoromethyl-
cyclohexanols 15 and 16.
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of the bulky Lewis acid methylaluminium bis(2,6-di-tert-butyl-
4-methyl)phenoxide to encourage the equatorial approach of
the nucleophile were unsuccessful.25 In addition, the more
sterically demanding trifluoromethylating agent hexafluoro-
acetone hydrate-1,8-diaza-bicyclo[5.4.0]undec-7-ene salt only
returned starting materials.26 However, 16 was successfully
prepared through the sequence outlined in Scheme 6.
Trifluoromethylation of the mono-protected cyclohexanedione
26 followed by deprotection and subsequent reductive amin-
ation27 gave the diastereomeric cis- and trans-isomers 16 and
15 in an 80 : 20 ratio, from which the required cis-isomer 16
could be isolated through purification by column chromato-
graphy in a poor but acceptable yield for the three steps (17%).
The relative configuration of both the trans- and cis-diastereo-
isomers 15 and 16 was confirmed through X-ray crystallo-
graphy (Fig. 5).
Conveniently, the four possible 1,2-isomers 13, 14, 19 and
20 could be prepared and isolated from a common intermedi-
ate, greatly simplifying the synthesis of these compounds
(Scheme 7). Intermediate 28 was prepared through a two-step
literature procedure involving the ring opening of cyclohexene
oxide 27 followed by Swern oxidation of the resulting amino-
alcohol to give 28 in 39% isolated yield (Scheme 7).20 Addition
of methylmagnesium chloride to 28 at 0 °C gave the cis-amino-
alcohol 14 in 89% isolated yield as a single isomer. Single
crystal X-ray analysis of the hydrochloride salt of 14 confirmed
the relative stereochemistry of this compound (Fig. 6) with the
methyl group adopting an equatorial position. Chelation of
the Grignard reagent to the carbonyl oxygen and the secondary
amine would be expected to deliver the methyl group from an
equatorial position, as was observed.
Changing the nucleophile to methyllithium resulted in the
formation of both the cis- and trans-products 14 and 13 in a
80 : 20 ratio (1H NMR analysis of the crude reaction mixture).
The isomers were separated by column chromatography, and
the 1H NMR spectrum of the minor trans-isomer 13 agreed
with the values reported for the product from ring-opening of
1-methylcyclohexene oxide by dibenzylamine.20 Therefore, the
diastereomers 13 and 14 can be accessed as single isomers in
good yield via two complimentary routes.
Treatment of 28 with Ruppert’s reagent and TBAF resulted
in a 80 : 20 mixture of the expected products 19 and 20, which
were purified by column chromatography and isolated in 58%
and 13% yields respectively (Scheme 7). The major diastereo-
mer was shown to be the trans-isomer 19 by single crystal X-ray
analysis (Fig. 7), and was supported by the observation of long
range splitting of the axial NC-H proton by the trans-CF3 group
in the 1H NMR spectrum. This coupling was not observed for
the cis-isomer 20.
Having successfully prepared each of the 1,4- and 1,2-
isomers our attention moved to the synthesis of the 1,3-substi-
tuted amino alcohols 11, 12, 17 and 18. Once again, these
could be prepared from a common intermediate (30), which
itself was prepared using a bismuth nitrate catalysed conjugate
addition of dibenzylamine to cyclohexenone 29 (Scheme 8).28
Isolation of the key intermediate 30 by chromatography proved
Scheme 6 Alternative synthesis of cis-4-dibenzylamino-1-triﬂuoro-
methylcyclohexanol (16).
Fig. 5 X-Ray crystal structure of 15 and 16.
Scheme 7 Synthesis of 2-dibenzylamino-1-substituted cyclohexan-1-ols 13, 14, 19 and 20.
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problematic due to decomposition of the adduct on silica,
however, direct crystallisation from the crude reaction mixture
using petroleum ether gave the amino ketone in 32% yield on
scale without the need for chromatography.
Addition of methylmagnesium chloride to 30 gave a 80 : 20
diastereomeric mixture of the expected trans-11 and cis-12 pro-
ducts, which were separated by column chromatography and
isolated in 80% and 9% yields respectively. The identity of the
major trans-isomer 11 was confirmed by single crystal X-ray
analysis where the dibenzylamino group adopted an equatorial
position (Fig. 8).
Treatment of 30 with Ruppert’s reagent in the presence of
TBAF gave a 50 : 50 mixture of the diastereomeric products 17
and 18, which were separated by column chromatography and
isolated in 37% and 41% yields respectively (Scheme 8). The
stereochemistry of cis-isomer 18 was deduced by 1H NMR
spectroscopy due to its intriguing behaviour in solution. In
CDCl3, 18 adopted a conformation (A) where the large
dibenzylamino group resided in an axial position due to an
intramolecular hydrogen bond, whereas in the H-bonding
deuterated solvent CD3OD the amino group adopted the
more common equatorial conformation (B) (Fig. 9).
This solvent-dependant conformational change has been
observed previously for cis-1,5,5-trimethylcyclohexane-1,3-diol
and cis-1,5,5-trimethyl-3-aminocyclohexanol in CDCl3/D2O,
29
but it is impressive that such a bulky dibenzylamino group dis-
plays this strong conformational fluxionality. The eﬀect can in
part be attributed to the size of the trifluoromethyl group,
although the fact that the eﬀect is reversed in CD3OD suggests
there is a hydrogen-bonding interaction involved (Fig. 9). Inter-
estingly, this is not seen in the methyl analogue 12 which
suggests that the trifluoromethyl group plays a pivotal role in
the conformation adopted by 18 in solution, presumably by
tuning the acidity of the alcohol.30 1H NMR analysis of 18·HCl
(in CDCl3) showed the dibenzylamino group in an equatorial
position, supporting the proposal that an intramolecular
hydrogen bond alters the conformational preference of 18 in
non-polar solvents.
This behaviour was further investigated through the prepa-
ration of a series of analogues of 18 (Scheme 9). Deprotection
of the amine through hydrogenolysis gave the amine 31 (94%)
which was acylated under standard conditions to give the
amide 32 (69%). Reduction of the amide with borane gave the
secondary amine 33 (76%).
The relative stereochemistry of amine 31 was confirmed by
single crystal X-ray where the amine substituent adopts an
Fig. 6 X-Ray crystal structure of 14·HCl.
Fig. 7 X-Ray crystal structure of trans-isomer 19.
Scheme 8 Synthesis of 3-dibenzylamino-1-substituted cyclohexanol derivatives.
Fig. 8 X-Ray crystal structure of major trans-1,3-isomer 11.
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axial conformation (Fig. 10). 1H NMR analysis of 31 showed
the NH2 group adopts an axial conformation in solution in
both CDCl3 and CD3OD showing the subtle interplay of sterics
and electronics in the benzylated analogue 18. Amide 32
and secondary amine 33 displayed the same conformational
behaviour, suggesting that all cis-3-amino-1-trifluoromethyl-
cyclohexanols possessing groups bonded to nitrogen that are
less bulky than two benzyl groups are likely to always adopt a
conformation with the amino functionality axial. This has
interesting implications for adopting these monomers in a
drug-discovery setting, where functional group disposition is
critical to ligand–receptor interaction. It is entirely feasible
that for compounds containing the cis-3-amino-cyclohexan-1-
ol motif as exemplified by 12 and 18, axial/equatorial confor-
mation could be controlled through incorporation of either a
methyl or a trifluoromethyl group.
Conclusion
The twelve isomers of amino-1-methylcyclohexan-1-ol and
amino-1-trifluoromethylcyclohexan-1-ol were successfully pre-
pared in three-steps or fewer from commercially available start-
ing materials. The stereochemistry of each isomer was
assigned via a combination of 1H NMR spectroscopy and
single crystal X-ray analysis. An interesting conformational
behaviour was observed and investigated for cis-3-amino-1-
trifluoromethylcyclohexan-1-ol derivatives, which could have
structural implications for molecules containing this motif.
This work provides robust routes to the isomers of amino-1-
methylcyclohexan-1-ol and amino-1-trifluoromethylcyclohexan-




All commercial materials were used as received without further
purification. THF was dried using a solvent purification
system. Flash chromatography was carried out using Merck
Kieselgel 60 H silica. Analytical thin layer chromatography was
carried out using aluminum-backed plates coated with Merck
Kieselgel 60 GF254 that were visualized under UV light (at
254 nm) or stained using KMnO4. Nuclear magnetic resonance
(NMR) spectra were recorded on a Bruker Avance III or a
Bruker Avance spectrometer, operating at 400 MHz (1H),
376 MHz (19F) and 101 MHz (13C). Chemical shifts were
reported in parts per million (ppm) in the scale relative to
residual solvent signals. Multiplicities are abbreviated as:
s, singlet; d, doublet; t, triplet; q, quartet; dd, doublet of
doublets; tt, triplet of triplets; pent; pentet; hept, heptet;
m, multiplet; br, broad. Coupling constants are measured
in Hertz (Hz). High-resolution mass spectra (HRMS) were
obtained courtesy of the EPSRC National Mass Spectrometry
Facility at Swansea University, U.K.
trans-4-(Dibenzylamino)cyclohexan-1-ol
Cesium carbonate (51.4 g, 158 mmol) was added to a solution
of trans-4-aminocyclohexanol (7.9 g, 52.3 mmol) in acetonitrile
(150 mL). Benzyl bromide (12.7 mL, 106 mmol) was added and
the mixture left to stir at room temperature for 2 days. The
crude reaction mixture was filtered, and the solid washed with
additional acetonitrile (100 mL). The filtrate was concentrated
under reduced pressure, dissolved in dichloromethane
(100 mL) and washed with water (3 × 50 mL). The organic
extract was dried over MgSO4, filtered and concentrated under
reduced pressure to give trans-4-(dibenzylamino)cyclohexan-
1-ol as a colourless solid (15.1 g, 98%); 1H NMR (400 MHz,
CDCl3) δ 7.37 (4H, d, J = 7.2 Hz), 7.29 (4H, ddd, J = 7.1, 6.1 Hz),
7.19–7.24 (2H, m), 3.62 (4H, s), 3.54 (1H, tt, J = 10.9, 4.3 Hz),
2.53 (1H, tt, J = 11.8, 3.5 Hz), 1.95–2.04 (2H, m), 1.87–1.94 (2H,
m), 1.36–1.61 (1H, br s), 1.36–1.49 (2H, m), 1.12–1.30 (2H, m);
13C NMR (100 MHz, CDCl3) δ 141.0 (quat C), 128.5 (CH),
Scheme 9 Derivatisation of the amine 18.
Fig. 10 X-Ray crystal structure of 31.
Fig. 9 Solvent-dependant conformational change of 18 in solution.
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128.3 (CH), 126.8 (CH), 71.0 (CH), 56.9 (CH), 54.1 (CH2),
35.0 (CH2), 26.0 (CH2); HRMS calc. for C20H26ON 296.2009
(M+ + 1), found 296.2011.
General Procedure 1. Swern oxidation
A solution of DMSO (11.6 mL, 163 mmol) in anhydrous
dichloromethane (20 mL) was added drop-wise via a dropping
funnel to a cooled solution of oxalyl chloride (6.8 mL,
80.8 mmol) in anhydrous dichloromethane (100 mL) at
−78 °C. The reaction mixture was left to stir for an additional
15 minutes following completion of addition, and a solution
of trans-4-(dibenzylamino)cyclohexan-1-ol (14.0 g, 47.5 mmol)
in anhydrous dichloromethane (50 mL) was added drop-wise
via a dropping funnel. Following completion of addition, the
reaction mixture was stirred for 30 minutes before triethyl-
amine (46 mL, 328 mmol) was added slowly drop-wise via
syringe, and the cooling bath removed to allow the reaction
mixture to warm to room temperature. The rubber septa were
removed to allow the evaporation of SMe2, and the mixture left
to stir overnight at room temperature. The crude reaction
mixture was concentrated under reduced pressure, dissolved
in ethyl acetate (150 mL) and washed with water (3 × 100 mL).
The organic extract was dried over MgSO4, filtered and concen-
trated under reduced pressure to give the crude product,
which was purified by column chromatography on silica (8 : 1
petroleum ether : ethyl acetate) to give 24 as peach coloured
solid (13.9 g, 86%); 1H NMR (400 MHz, CDCl3) δ 7.38 (4H, d,
J = 7.2 Hz), 7.29–7.34 (4H, m), 7.21–7.26 (2H, m), 3.66 (4H, s),
3.02 (1H, tt, J = 11.5, 3.4 Hz), 2.37–2.45 (2H, m), 2.12–2.33 (4H,
m), 1.76–1.89 (2H, m); 13C NMR (100 MHz, CDCl3) δ 211.1
(quat C), 140.4 (quat C), 128.5 (CH), 128.4 (CH), 127.0 (CH),
55.9 (CH), 54.2 (CH2), 40.3 (CH2), 27.5 (CH2); HRMS calc. for
C20H24ON 294.1852 (M
+ + 1), found 294.1854.
General Procedure 2. Addition of methylmagnesium chloride
To a solution of 24 (4.41 g, 15.05 mmol) in anhydrous THF
(45 mL) cooled to −78 °C under a N2 atmosphere, was added
3.0 M MeMgCl in THF (8.02 mL, 24.06 mmol) drop-wise. Fol-
lowing completion of addition, the cooling bath was removed
and the reaction mixture left to warm to room temperature
and stirred overnight. Water (10 mL) was added drop-wise, and
the aqueous layer extracted with diethyl ether (3 × 20 mL). The
combined organic extracts were washed with water (20 mL)
and brine (20 mL), dried over MgSO4, filtered and concen-
trated under reduced pressure to give the crude products,
which were purified by column chromatography on silica (5 : 1
petroleum ether : ethyl acetate followed by 4 : 1 and finally
3 : 1) to give 10 as a colourless solid (2.62 g, 56%); 1H NMR
(400 MHz, CDCl3) δ 7.38 (4H, d, J = 7.2 Hz), 7.29 (4H, app t, J =
7.6 Hz), 7.21 (2H, t, J = 7.3 Hz), 3.67 (4H, s), 2.43–2.53 (1H, m),
1.62–1.83 (6H, m), 1.25–1.38 (2H, m), 1.17 (3H, s); 13C NMR
(100 MHz, CDCl3) δ 141.2 (quat C), 128.5 (CH), 128.2 (CH),
126.7 (CH), 69.2 (quat C), 57.2 (CH), 54.1 (CH2), 38.5 (CH2),
31.4 (CH3), 23.5 (CH2); HRMS calc. for C21H28ON 310.2165
(M+ + 1), found 310.2157. A sample was crystallised by slow
evaporation of a solution in cyclohexane. Followed by 9 as a
colourless solid (0.85 g, 18%); 1H NMR (400 MHz, CDCl3)
δ 7.36 (4H, d, J = 7.1 Hz), 7.26–7.31 (4H, m), 7.21 (2H, dt, J =
7.2, 1.3 Hz), 3.63 (4H, s), 2.56 (1H, tt, J = 11.6, 3.7 Hz),
1.78–1.88 (2H, m), 1.67–1.77 (2H, m), 1.32–1.55 (4H, m), 1.25
(3H, s); 13C NMR (100 MHz, CDCl3) δ 141.0 (quat C), 128.5
(CH), 128.3 (CH), 126.8 (CH), 71.0 (quat C), 57.5 (CH), 54.3
(CH2), 39.8 (CH2), 25.6 (CH2), 25.5 (CH3); HRMS calc. for
C21H28ON 310.2165 (M
+ + 1), found 310.2168. Crystals were
grown by slow evaporation of a solution in cyclohexane.
General Procedure 3. Reaction with Ruppert’s reagent
To a solution of 24 (2.0 g, 6.83 mmol) in anhydrous THF
(15 mL) cooled to 0 °C, was added trifluoromethyltrimethyl-
silane (1.2 mL, 8.20 mmol) under a N2 atmosphere. The
mixture was stirred rapidly, and a solution of TBAF (5 mg, cat)
in anhydrous THF (1 mL) was added slowly drop-wise. Follow-
ing completion of addition, the cooling bath was removed and
the reaction mixture left to warm to room temperature and
stirred until consumption of starting material was apparent by
TLC (1.5 h). The reaction mixture was exposed to air, 4 M HCl
(aq) solution (10 mL) was added and the reaction mixture left
to stir at room temperature until consumption of the siloxy
intermediate was apparent by TLC (2 h). The pH was adjusted
to 7 by the drop-wise addition of a saturated solution of
K2CO3, and dichloromethane (30 mL) was added. The mixture
was washed with water (3 × 15 mL), dried over MgSO4, filtered
and concentrated under reduced pressure to give the crude
product, which was purified by column chromatography on
silica (10 : 1 petroleum ether : ethyl acetate) to give 15 and 16
as a colourless solid as a 9 : 1 trans : cis mixture of diastereo-
mers (2.0 g, 81%). A small amount of pure trans-15 was
obtained and used for characterisation purposes; 1H NMR
(400 MHz, CDCl3) δ 7.27–7.36 (8H, m), 7.19–7.24 (2H, m), 3.65
(4H, s), 2.73 (1H, pent, J = 6.3 Hz), 2.18 (2H, app dt, J = 10.7,
4.5 Hz), 1.83 (4H, app q, J = 6.7 Hz), 1.52–1.57 (1H, br s), 1.47
(2H, app dt, J = 14.0, 7.0 Hz); 13C NMR (100 MHz, CDCl3)
δ 140.3 (quat C), 128.6 (CH), 128.3 (CH), 126.9 (CH), 126.8
(quat C, q, J = 283 Hz), 72.4 (quat C, q, J = 30.3 Hz), 55.3 (CH),
53.9 (CH2), 29.9 (CH2), 23.5 (CH2);
19F{1H} NMR (376 MHz,
CDCl3) δ −80.1; HRMS calc. for C21H25ONF3 364.1883 (M
+ + 1),
found 364.1882; Crystals obtained from cold toluene.
4-Oxo-1-(trifluoromethyl)cyclohexan-1-ol
4-Oxo-1-(trifluoromethyl)cyclohexan-1-ol was prepared using
General Procedure 3 (reaction mixture was stirred overnight at
rt following addition of 4 M HCl (aq) solution) from 1,4-dioxa-
spiro[4.5]decan-8-one (2.00 g, 12.8 mmol), trifluoromethyltri-
methylsilane (2.08 mL, 14.1 mmol), anhydrous THF (30 mL)
and a solution of TBAF (5 mg) in THF (1.0 mL) to give the
crude product, which was purified by column chromatography
on silica (3 : 1 petroleum ether : ethyl acetate) to give 4-oxo-
1-trifluoromethylcyclohexan-1-ol as a colourless solid (1.28 g,
55%); 1H NMR (400 MHz, d6-Acetone) δ 5.30 (1H, s), 2.69
(2H, ddd, J = 14.4, 6.4, 6.4 Hz), 2.06–2.27 (6H, m); 13C NMR
(100 MHz, d6-Acetone) δ 208.3 (quat C), 127.7 (quat C, q, J =
308 Hz), 71.8 (quat C, q, J = 22 Hz), 35.8 (CH2), 30.4 (CH2);
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19F{1H} NMR (376 MHz, d6-Acetone) δ −93.4; HRMS calc. for
C7H8O2F3 181.0482 (M
+
− 1), found 181.0485.
cis-4-(Dibenzylamino)-1-(trifluoromethyl)cyclohexan-1-ol 16
Following the procedure reported by Abdel-Magid,27 4-oxo-
1-trifluoromethylcyclohexan-1-ol (0.20 g, 1.1 mmol), dibenzyl-
amine (0.21 mL, 1.1 mmol), NaBH(OAc)3 (0.33 g, 1.5 mmol)
and acetic acid (0.13 mL, 2.2 mmol) were mixed in anhydrous
THF (5 mL). The resulting mixture was stirred under an Ar
atmosphere for 16 h, before further portions of NaBH(OAc)3
(0.33 g, 1.5 mmol) and acetic acid (0.13 mL, 2.2 mmol) were
added and the mixture stirred for a further 6 h. The reaction
mixture was quenched with 1 M NaOH (aq) solution (20 mL),
poured into a separating funnel and extracted with dichloro-
methane (3 × 15 mL). The combined organic extract was
washed with water (20 mL), dried over MgSO4, filtered and
concentrated under reduced pressure to give the crude
product, which was purified by column chromatography on
silica (6 : 1 petroleum ether : ethyl acetate) to give cis 16 (0.12 g,
31%); 1H NMR (400 MHz, CDCl3) δ 7.38 (4H, d, J = 7.2 Hz),
7.31 (4H, app t, J = 7.2 Hz), 7.23 (2H, t, J = 7.2 Hz), 3.68 (4H, s),
2.46–2.62 (1H, m), 1.72–1.90 (6H, m), 1.67 (1H, br s), 1.55 (1H,
app td, J = 12.5, 5.1 Hz); 13C NMR (100 MHz, CDCl3) δ 140.8
(quat C), 128.5 (CH), 128.4 (CH), 126.9 (CH), 126.4 (quat C, q,
J = 280 Hz), 72.5 (quat C, q, J = 30 Hz), 56.6 (CH), 54.0 (CH2),
29.7 (CH2), 22.0 (CH2);
19F{1H} NMR (376 MHz, CDCl3)
δ −84.5; HRMS calc. for C21H25ONF3 364.1883 (M
+ + 1), found
364.1880. Crystals were grown by slow evaporation of a satu-
rated solution in CHCl3.
trans-2-(Dibenzylamino)cyclohexan-1-ol
Following the procedure reported by Yamamoto,20 dibenzyl-
amine (3.9 mL, 20.0 mmol) was added to a mixture of cyclo-
hexene oxide (1.0 mL, 10.0 mmol), ytterbium triflate (0.62 g,
1.0 mmol) and anhydrous THF (10 mL). The mixture was
refluxed under an Ar atmosphere for 14 h. Ethyl acetate
(30 mL) was added, and the solution was washed with a satu-
rated solution of K2CO3 (20 mL), dried over MgSO4, filtered
and concentrated under reduced pressure to give the crude
product, which was purified by column chromatography on
silica (9 : 1 petroleum ether : ethyl acetate) to give trans-
2-(dibenzylamino)cyclohexan-1-ol as a colourless solid (1.5 g,
50%); 1H NMR (500 MHz, CDCl3) δ 7.22–7.36 (10H, m), 3.87
(2H, d, J = 13.3 Hz), 3.73–3.77 (1H, br s), 3.52 (1H, app td, J =
10.1, 4.5 Hz), 3.40 (2H, d, J = 13.3 Hz), 2.37 (1H, ddd, J = 10.9,
10.6, 3.5 Hz), 2.04–2.12 (1H, m), 1.96–2.02 (1H, m), 1.75–1.85
(1H, m), 1.61–1.72 (1H, m), 1.05–1.33 (4H, m); 13C NMR
(100 MHz, CDCl3) δ 139.6 (quat C), 129.1 (CH), 128.6 (CH),
127.3 (CH), 69.2 (CH), 64.3 (CH), 53.7 (CH2), 33.3 (CH2), 25.6
(CH2), 24.2 (CH2), 22.2 (CH2); HRMS calc. for C20H26ON
296.2009 (M+ + 1), found 296.2010.
2-(Dibenzylamino)cyclohexan-1-one 28
Compound 28 was prepared using General Procedure 1 from
trans-2-(dibenzylamino)cyclohexan-1-ol (1.20 g, 4.1 mmol),
oxalyl chloride (0.48 mL, 5.6 mmol), DMSO (1.00 mL,
14.1 mmol), triethylamine (3.92 mL, 28.1 mmol) and anhydrous
dichloromethane (30 mL in total) to give the crude product,
which was purified by column chromatography on silica (8 : 1
petroleum ether : ethyl acetate) to give 28 as a light yellow solid
(0.93 g, 78%); 1H NMR (400 MHz, CDCl3) δ 7.39 (4H, d, J =
7.2 Hz), 7.26–7.32 (4H, m), 7.18–7.24 (2H, m), 4.00 (2H, d, J =
14.3 Hz), 3.76 (2H, d, J = 14.3 Hz), 3.31 (1H, dd, J = 12.4, 5.7),
2.34–2.44 (1H, m), 2.10–2.25 (2H, m), 1.76–2.02 (3H, m),
1.44–1.66 (2H, m); 13C NMR (100 MHz, CDCl3) δ 212.2 (quat C),
140.8 (quat C), 128.5 (CH), 128.3 (CH), 126.9 (CH), 66.6 (CH),
54.9 (CH2), 42.6 (CH2), 31.7 (CH2), 27.2 (CH2), 25.1 (CH2);
HRMS calc. for C20H24ON 294.1852 (M
+ + 1), found 294.1852.
cis-2-(Dibenzylamino)-1-methylcyclohexan-1-ol 14
Compound 14 was prepared following General Procedure 2 at a
reduced temperature of 0 °C, from 28 (0.25 g, 0.85 mmol),
anhydrous THF (10 mL) and 3.0 M MeMgCl in THF (0.45 mL,
1.35 mmol), and was isolated as a yellow oil (0.23 g, 89%);
1H NMR (400 MHz, CDCl3) δ 7.39 (4H, d, J = 7.3 Hz), 7.30 (4H,
app t, J = 7.3 Hz), 7.22 (2H, t, J = 7.3 Hz), 4.14 (2H, d, J =
13.8 Hz), 3.39 (2H, d, J = 13.8 Hz), 2.29 (1H, dd, J = 12.2,
3.4 Hz), 1.80–1.90 (2H, m), 1.65–1.79 (1H, m), 1.48–1.57 (2H,
m), 1.38–1.48 (1H, m), 1.08–1.27 (5H, m); 13C NMR (100 MHz,
CDCl3) δ 141.2 (quat C), 129.0 (CH), 128.2 (CH), 126.7 (CH),
74.3 (quat C), 63.1 (CH), 55.9 (CH2), 41.4 (CH2), 29.2 (CH3),
26.4 (CH2), 21.8 (CH2), 20.1 (CH2); HRMS calc. for C21H28ON
310.2165 (M+ + 1), found 310.2166. The HCl salt of 14 was pre-
pared by forming a saturated HCl solution in diethyl ether.
Crystals were grown by the slow evaporation of a concentrated
solution of the salt 14·HCl in methanol.
trans-2-(Dibenzylamino)-1-methylcyclohexan-1-ol 13 and
cis-2-(dibenzylamino)-1-methylcyclohexan-1-ol 14
Compounds 13 and 14 were prepared following General Pro-
cedure 2 at a reduced temperature of 0 °C, using 28 (0.050 g,
0.17 mmol), dry THF (10 mL) and a 1.6 M solution of MeLi in
diethyl ether (0.16 mL, 0.26 mmol) to give the crude products,
which were purified by column chromatography on silica
(10 : 1 petroleum ether : ethyl acetate) to give 14 (0.023 g, 44%)
which was identical to an authentic sample, followed by 13 as
a colourless residue (0.007 g, 13%); 1H NMR (400 MHz, CDCl3)
δ 7.17–7.46 (10H, m), 3.85 (2H, d, J = 13.7 Hz), 3.42 (2H, d, J =
13.7 Hz), 2.61 (1H, app d, J = 10.6 Hz, CH), 1.84, (2H, app d, J =
8.8 Hz), 1.50–1.72 (4H, m), 1.36–1.47 (2H, m), 1.27 (3H, s);
HRMS calc. for C21H28ON 310.2165 (M
+ + 1), found 310.2166.
trans-2-(Dibenzylamino)-1-(trifluoromethyl)cyclohexan-1-ol 19
and cis-2-(dibenzylamino)-1-(trifluoromethyl)cyclohexan-1-ol 20
Compounds 19 and 20 were prepared using General Procedure
2 in which 4 M HCl was added after 3 h, using 28 (0.234 g,
0.80 mmol), trifluoromethyltrimethylsilane (0.14 mL,
0.95 mmol), anhydrous THF (10 mL) and a solution of TBAF
(5 mg) in THF (1.0 mL) to give the crude products, which were
purified by column chromatography on silica (5 : 1, followed by
5 : 2 petroleum ether : ethyl acetate) to give 19 as a colourless
solid (0.167 g, 58%); 1H NMR (400 MHz, CDCl3) δ 7.26–7.44
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(10H, m), 3.69–4.15 (2H, br s), 3.63 (1H, s), 3.36 (2H, d, J =
13.3 Hz), 2.78–2.89 (1H, m), 2.21–2.31 (1H, m), 1.91–2.01 (2H,
m), 1.75–1.91 (1H, m), 1.28–1.69 (3H, m), 1.19 (1H, dddd, J =
16.4, 9.4, 4.6, 2.3 Hz); 13C NMR (100 MHz, CDCl3) δ 139.4 (quat
C), 129.2 (CH), 128.7 (CH), 127.6 (CH), 127.2 (quat C, q, J =
293.0 Hz), 72.3 (quat C, q, J = 20.1 Hz), 66.3 (CH), 55.9
(CH2, br), 34.1 (CH2), 26.0 (CH2), 21.5 (CH2), 21.4 (CH2);
19F{1H} NMR (376 MHz, CDCl3) δ −69.4; HRMS calc. for
C21H25ONF3 364.1883 (M
+ + 1), found 364.1878; crystallised
from cold MeOH. Followed by 20 as a colourless solid (0.037 g,
13%); 1H NMR (400 MHz, CDCl3) δ 7.38–7.46 (4H, m), 7.35
(4H, app t, J = 7.2 Hz), 7.28 (2H, t, J = 7.2 Hz), 3.66–4.38 (2H, br
s), 3.52 (2H, d, J = 13.8 Hz), 3.00 (1H, dd, J = 10.1, 4.4 Hz),
2.31–2.58 (1H, m), 1.72–1.94 (4H, m), 1.47–1.64 (3H, m),
1.16–1.40 (1H, m); 13C NMR (100 MHz, CDCl3) δ 139.7
(quat C), 129.2 (CH), 128.4 (CH), 127.1 (CH), 126.4 (quat C, q,
J = 293.0 Hz), 76.3 (quat C, q, J = 20.2 Hz), 58.6 (CH), 55.5
(CH2, br), 32.8 (CH2), 25.2 (CH2), 20.8 (CH2), 20.5 (CH2);
19F{1H} NMR (376 MHz, CDCl3) δ −78.2; HRMS calc. for
C21H25ONF3 364.1883 (M
+ + 1), found 364.1883.
3-(Dibenzylamino)cyclohexan-1-one 30
Following the procedure reported by Banik and Srivastava,28
bismuth(III) nitrate pentahydrate (10.0 g, 21 mmol) was added
to a solution of cyclohexen-1-one (10 mL, 103 mmol) and
dibenzylamine (20 mL, 104 mmol) in dichloromethane (80 mL).
Most of the dichloromethane was removed under reduced
pressure, and the resulting slurry stirred at room temperature
overnight. Dichloromethane (100 mL) was added and the result-
ing suspension filtered by gravity filtration through filter paper.
The filtrate was washed with sat. NaHCO3 (2 × 30 mL) and brine
(2 × 30 mL), dried over MgSO4, filtered once again and the
dichloromethane removed under reduced pressure (taking care
not to heat above 40 °C) to give the crude product. Purification
was achieved by twice recrystallising from warm petroleum
ether to give 30 as colourless crystals (9.7 g, 32%); 1H NMR
(400 MHz, CDCl3) δ 7.36 (4H, d, J = 7.0 Hz), 7.27–7.33 (4H, m),
7.20–7.25 (2H, m), 3.72 (2H, d, J = 14.0 Hz), 3.62 (2H, d, J =
14.0 Hz), 2.95 (1H, app tt, J = 12.2, 3.7 Hz), 2.61–2.69 (1H, m),
2.39–2.49 (1H, m), 2.27–2.36 (1H, m), 2.15–2.27 (1H, m),
1.95–2.13 (2H, m), 1.65–1.78 (1H, m), 1.61–1.69 (1H, br s),
1.33–1.48 (1H, m); 13C NMR (100 MHz, CDCl3) δ 210.8 (quat C),
140.0 (quat C), 128.5 (CH), 128.4 (CH), 127.1 (CH), 58.2 (CH),
53.8 (CH2), 44.3 (CH2), 41.3 (CH2), 27.9 (CH2), 22.6 (CH2);
HRMS calc. for C20H24ON 294.1852 (M
+ + 1), found 294.1855.
trans-3-(Dibenzylamino)-1-methylcyclohexan-1-ol 11 and
cis-3-(dibenzylamino)-1-methylcyclohexan-1-ol 12
Compounds 11 and 12 were prepared following General Proce-
dure 2 at a reduced temperature of 0 °C, using 30 (0.40 g,
1.36 mmol), anhydrous THF (15 mL) and 3.0 M MeMgCl in
THF (0.73 mL, 2.18 mmol), and the products purified by
column chromatography on silica (6 : 1 petroleum ether : ethyl
acetate) to give 11 as a colourless solid (0.34 g, 80%); 1H NMR
(400 MHz, CDCl3) δ 7.36 (4H, d, J = 7.4 Hz), 7.28 (4H, app t, J =
7.4 Hz), 7.19 (2H, t, J = 7.4 Hz), 3.63 (3H, s), 2.92 (1H, app tt,
J = 12.2, 3.4 Hz), 1.80–1.95 (2H, m), 1.36–1.67 (4H, m),
1.15–1.30 (5H, m), 0.98 (1H, br s); 13C NMR (100 MHz, CDCl3)
δ 141.1 (quat C), 128.6 (CH), 128.3 (CH), 126.7 (CH), 71.0
(quat C), 54.0 (CH2), 53.7 (CH), 41.1 (CH2), 38.7 (CH2), 32.1
(CH3), 27.7 (CH2), 20.7 (CH2); HRMS calc. for C21H28ON
310.2165 (M+ + 1), found 310.2164; crystallised from cold
MeOH. Followed by 12 as a colourless oil that solidified on
standing (0.04 g, 9%); 1H NMR (400 MHz, CDCl3) δ 7.27–7.39
(8H, m), 7.22 (2H, t, J = 7.0 Hz), 3.71 (2H, d, J = 14.0 Hz), 3.65
(2H, d, J = 14.0 Hz), 2.74 (1H, app tt, J = 9.4, 3.4 Hz), 1.64–1.85
(4H, m), 1.39–1.62 (3H, m), 1.17–1.30 (1H, m), 1.12 (3H, s,
CH3);
13C NMR (100 MHz, CDCl3) δ 140.0 (quat C), 128.9 (CH),
128.3 (CH), 126.9 (CH), 71.6 (quat C), 55.3 (CH), 53.6 (CH2),
41.1 (CH2), 40.4 (CH2), 28.6 (CH2), 27.4 (CH3), 21.0 (CH2);
HRMS calc. for C21H28ON 310.2165 (M
+ + 1), found 310.2160.
trans-3-(Dibenzylamino)-1-(trifluoromethyl)cyclohexan-1-ol 17
and cis-3-(dibenzylamino)-1-(trifluoromethyl)cyclohexan-1-ol 18
Compounds 17 and 18 were prepared following General
Procedure 3 quenching with 4 M HCl after 2.5 h, from 30
(1.40 g, 4.75 mmol), trifluoromethyltrimethylsilane (0.77 mL,
5.21 mmol), anhydrous THF (20 mL) and a solution of TBAF
(5 mg) in THF (1.0 mL) to give the crude products, which were
purified by column chromatography on silica (3 : 1 petroleum
ether : ethyl acetate) to give 17 as a colourless solid (0.64 g,
37%); 1H NMR (400 MHz, CDCl3) δ 7.36 (4H, d, J = 7.3 Hz),
7.30 (4H, app t, J = 7.4 Hz), 7.22 (2H, t, J = 7.4 Hz), 3.62 (4H, br
s), 1.89–2.03 (1H, m), 1.89–2.02 (2H, m), 1.42–1.79 (6H, m),
1.27–1.41 (1H, m); 13C NMR (100 MHz, CDCl3) δ 140.5
(quat C), 128.6 (CH), 128.4 (CH), 126.9 (CH), 126.1 (quat C, q,
J = 283 Hz), 74.5 (quat C, q, J = 30.3 Hz), 53.9 (CH2), 52.3 (CH),
32.1 (CH2), 29.7 (CH2), 27.4 (CH2), 19.7 (CH2);
19F{1H} NMR
(376 MHz, CDCl3) δ −84.8; HRMS calc. for C21H25ONF3
364.1883 (M+ + 1), found 364.1885. Followed by 18 as a colour-
less solid (0.70 g, 41%); 1H NMR (400 MHz, CDCl3) δ 7.39–7.48
(1H, br s), 7.29–7.36 (4H, m), 7.22–7.29 (6H, m), 3.81 (2H, d,
J = 14.3 Hz), 3.76 (2H, d, J = 14.3 Hz), 3.19 (1H, app pent, J =
3.2 Hz), 2.48 (1H, app d, J = 14.1 Hz), 2.03–2.17 (1H, app d, J =
14.3 Hz), 1.83–1.95 (1H, app d, J = 11.6 Hz), 1.44–1.82 (5H, m);
1H NMR (400 MHz, CD3OD) δ 7.25–7.34 (8H, m), 7.17–7.23
(2H, m), 3.68 (2H, d, J = 13.8 Hz), 3.61 (2H, d, J = 13.8 Hz), 2.91
(1H, app tt, J = 10.8, 3.6 Hz), 2.18–2.28 (1H, m), 1.95–2.05 (1H,
m), 1.75–1.84 (1H, m), 1.62–1.74 (2H, m), 1.26–1.60 (3H, m);
13C NMR (100 MHz, CDCl3) δ 137.3 (quat C), 129.5 (CH), 128.7
(CH), 127.6 (CH), 126.0 (quat C, q, J = 284 Hz), 73.8 (quat C, q,
J = 28.7 Hz), 54.9 (CH), 53.2 (CH2), 31.2 (CH2), 30.2 (CH2), 28.3
(CH2), 16.4 (CH2);
19F{1H} NMR (376 MHz, CDCl3) δ −84.4;
HRMS calc. for C21H25ONF3 364.1883 (M
+ + 1), found 364.1885.
cis-3-Amino-1-(trifluoromethyl)cyclohexan-1-ol 31
Pearlman’s catalyst (10% palladium hydroxide on carbon,
0.49 g, 5.38 mmol) and 18 (1.96 g, 0.538 mmol) were added to
a Schlenk flask which was evacuated and back-filled with N2.
Ethanol (20 mL) was added and the flask evacuated using a
diaphragm pump and back-filled with H2 from a balloon three
times. The reaction mixture was left to stir vigorously until
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consumption of starting material was apparent by TLC analysis
(2 days at room temperature). Ethyl acetate (20 mL) was added,
and the mixture passed through a short Celite plug using
additional ethyl acetate. The filtrate was concentrated under
reduced pressure to give 31 as a light yellow oil, which crystal-
lised upon standing (0.93 g, 93%); 1H NMR (400 MHz, CDCl3)
δ 3.35–3.30 (1H, m), 1.86–1.96 (2H, m), 1.79–1.82 (2H, m,),
1.74–1.78 (1H, m), 1.64–1.74 (2H, m), 1.54–1.63 (1H, m);
13C NMR (100 MHz, CDCl3) δ 127.5 (quat C, q, J = 283.0 Hz),
74.0 (quat C, q, J = 30.3 Hz), 46.8 (CH), 35.3 (CH2), 32.9 (CH2),
31.2 (CH2), 16.5 (CH2);
19F{1H} NMR (376 MHz, CDCl3)
δ −85.2; HRMS calc. for C7H13ONF3 184.0944 (M




3-(4-Methoxyphenyl)propionic acid (0.79 g, 4.38 mmol) was
refluxed in thionyl chloride (0.58 mL, 8.0 mmol) under an
atmosphere of N2 for 2 h. Excess thionyl chloride was removed
under reduced pressure to give the crude acid chloride, which
was used without further purification. In a separate flask, a
solution of 31 (0.73 g, 3.99 mmol) and triethylamine (0.61 mL,
4.38 mmol) in anhydrous diethyl ether (20 mL) under a N2
atmosphere was cooled to 0 °C. A solution of the freshly pre-
pared acid chloride in anhydrous ether (2 mL) was added
drop-wise with vigorous stirring of the reaction mixture. Upon
completion of addition, the cooling bath was removed and the
mixture left to stir overnight at room temperature. The reaction
mixture was poured into a separating funnel containing water
(20 mL), and was extracted with ethyl acetate (3 × 15 mL).
The combined organic extract was washed with 1 M HCl
(2 × 20 mL), water (20 mL), dried over MgSO4, filtered and con-
centrated under reduced pressure to give the crude product,
which was purified by column chromatography on silica
(1 : 9 methanol : ethyl acetate) to give 32 as a yellow oil (0.96 g,
69%); 1H NMR (400 MHz, CDCl3) δ 7.10 (2H, d, J = 8.6 Hz),
6.81 (2H, d, J = 8.6 Hz), 6.77 (1H, br d, J = 8.2 Hz), 4.28–4.36
(1H, m), 3.76 (3H, s), 2.88 (2H, t, J = 7.4 Hz), 2.40 (2H, t, J =
7.4 Hz), 1.67–1.83 (4H, m), 1.48–1.64 (3H, m), 1.32–1.42 (1H,
m); 13C NMR (100 MHz, CDCl3) δ 171.3 (quat C), 158.3
(quat C), 132.9 (quat C), 129.5 (CH), 125.8 (quat C, q, J =
289 Hz), 114.1 (CH), 73.6 (quat C, q, J = 28 Hz), 55.4 (CH3),
42.9 (CH), 39.3 (CH2), 32.3 (CH2), 31.2 (CH2), 29.8 (CH2),
29.3 (CH2), 15.1 (CH2);
19F{1H} NMR (376 MHz, CDCl3)
δ −85.1; HRMS calc. for C17H23O3NF3 346.1625 (M




To a solution of 32 (0.93 g, 2.69 mmol) in anhydrous THF
(25 mL) under a N2 atmosphere, was added drop-wise a 1 M
solution of BH3·THF (27.0 mL, 27.0 mmol). Upon completion
of addition, the mixture was heated at reflux overnight. The
reaction mixture was cooled to 0 °C and methanol (5 mL) was
added carefully drop-wise and the mixture stirred at room
temperature for 1 hour. 2 M HCl (aq) (5 mL) was added, and
the mixture was stirred for an additional 30 minutes at room
temperature, after which the volatiles were removed under
reduced pressure to give the aqueous residue. The aqueous
residue was adjusted to pH 10 using 2 M NaOH (aq), and
extracted with ethyl acetate (3 × 20 mL). The combined organic
extracts were washed with brine (20 mL), dried over MgSO4, fil-
tered and concentrated under reduced pressure to give the
crude product, which was purified by column chromatography
on silica (3 : 1 dichloromethane : methanol) to give 33 as a
light yellow oil (0.68 g, 76%); 1H NMR (400 MHz, CDCl3) δ 7.10
(2H, d, J = 8.8 Hz), 6.83 (2H, d, J = 8.8 Hz), 3.78 (3H, s), 3.65
(1H, app t, J = 6.4 Hz), 3.14 (1H, app pent, J = 3.0 Hz), 2.46–2.77
(4H, m), 1.67–2.03 (7H, m), 1.43–1.65 (4H, m); 13C NMR
(100 MHz, CDCl3) δ 158.0 (quat C), 133.7 (quat C), 129.4 (CH),
125.8 (quat C, q, J = 281 Hz), 114.0 (CH), 73.4 (quat C, q, J =
30 Hz), 55.4 (CH3), 53.0 (CH), 47.0 (CH2), 34.5 (CH2),
32.6 (CH2), 31.8 (CH2), 31.3 (CH2), 30.6 (CH2), 15.3 (CH2);
19F{1H} NMR (376 MHz, CDCl3) δ −85.2; HRMS calc. for
C17H25O2NF3 332.1832 (M
+ + 1), found 332.1836.
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